Review



dx eplex blood culture id (gram-negative) bcid-gn  (GenMark Diagnostics)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GenMark Diagnostics dx eplex blood culture id (gram-negative) bcid-gn
    Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based <t>on</t> <t>GenMark</t> ePlex BCID <t>RUO</t> or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).
    Dx Eplex Blood Culture Id (Gram Negative) Bcid Gn, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dx eplex blood culture id (gram-negative) bcid-gn/product/GenMark Diagnostics
    Average 90 stars, based on 1 article reviews
    dx eplex blood culture id (gram-negative) bcid-gn - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)"

    Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

    Journal: Antimicrobial Agents and Chemotherapy

    doi: 10.1128/AAC.00441-21

    Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).
    Figure Legend Snippet: Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

    Techniques Used: Comparison



    Similar Products

    dx eplex blood culture id (gram-negative) bcid-gn  (GenMark Diagnostics)
    90
    GenMark Diagnostics dx eplex blood culture id (gram-negative) bcid-gn
    Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based <t>on</t> <t>GenMark</t> ePlex BCID <t>RUO</t> or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).
    Dx Eplex Blood Culture Id (Gram Negative) Bcid Gn, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dx eplex blood culture id (gram-negative) bcid-gn/product/GenMark Diagnostics
    Average 90 stars, based on 1 article reviews
    dx eplex blood culture id (gram-negative) bcid-gn - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    dx eplex blood culture id (bcid  (GenMark Diagnostics)
    90
    GenMark Diagnostics dx eplex blood culture id (bcid
    Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of <t>ePlex</t> <t>BCID</t> panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).
    Dx Eplex Blood Culture Id (Bcid, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dx eplex blood culture id (bcid/product/GenMark Diagnostics
    Average 90 stars, based on 1 article reviews
    dx eplex blood culture id (bcid - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

    doi: 10.1128/AAC.00441-21

    Figure Lengend Snippet: Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

    Article Snippet: Before discrepancy analysis, the GenMark Dx ePlex blood culture ID (Gram-negative) (BCID-GN) research use only (RUO) panel missed 1 Pseudomonas aeruginosa , 2 Stenotrophomonas maltophilia , and 1 Escherichia coli isolate for a positive percent agreement (PPA) of 95.2% (95% confidence interval [CI], 88.3 to 98.7).

    Techniques: Comparison

    Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

    doi: 10.1128/AAC.00441-21

    Figure Lengend Snippet: Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

    Article Snippet: An observational study was performed at University of Maryland Medical System comparing Verigene blood culture (BC) to GenMark Dx ePlex blood culture ID (BCID) (research use only) panels on blood cultures from adult patients.

    Techniques:

    Comparison of RDT platforms

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

    doi: 10.1128/AAC.00441-21

    Figure Lengend Snippet: Comparison of RDT platforms

    Article Snippet: An observational study was performed at University of Maryland Medical System comparing Verigene blood culture (BC) to GenMark Dx ePlex blood culture ID (BCID) (research use only) panels on blood cultures from adult patients.

    Techniques: